Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2019

View Archived Issues

Identification of variants in CTSD and ACP2 genes that could be protective against Parkinson's

Mutations in CFTR associated with development of COPD

Novel minigastrin analogue for PET imaging of CCK2R-expressing tumors

[68Ga]Ga-ProBOMB2 is a promising new GRPR-imaging PET radiotracer

Roche patents new antibacterials

Improved PSMA-targeting radiotherapeutic agents developed for prostate cancer

Phenex Discovery Verwaltungs discloses IDO1 inhibitors

Bayer synthesizes new AMPK inhibitors

Istituto Oncologico di Ricerca describes new compounds for cancer

Chinese investigators present UFO inhibitors

"Itchy" gut leads to pain sensitivity in IBS

Why smokers are prone to diabetes

AP2A2 gene tied to hereditary spastic paraplegia

University Hospital Heidelberg describes clinical testing of 18F-labeled FAPI tracer

IMbrave150 study of Tecentriq with Avastin in HCC meets coprimary endpoints

Phase II study of CV-301 in bladder cancer does not meet efficacy threshold to progress

Xuzhou Medical University describes CAR-T therapy targeting HBVsAg

Ultomiris approved in U.S. for atypical hemolytic uremic syndrome

FDA approves Farxiga to reduce risk of hospitalization for heart failure in type 2 diabetes patients

FDA grants approval to Amzeeq topical foam for acne

Primary endpoint met in HER2CLIMB trial of tucatinib in HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...